PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Andexanet alfa - Anticoagulation reversal

PAD Profile : Andexanet alfa - Anticoagulation reversal

Keywords :
Factor Xa inhibitor, apixaban antidote, apixaban reversal, rivaroxaban antidote, rivaroxaban reversal, anticoagulant reversal
Brand Names Include :
Ondexxya

Traffic Light Status

Status 1 of 1.

Status :
Red
Important
Formulations :
  • Infusion
Important Information :
Apixaban / rivaroxaban anticoagulant reversal. RESTRICTED to Haematologists only
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
04 August 2021
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed andexanet alfa, as an alternative treatment option, for reversing anticoagulation from apixaban or rivaroxaban,in adults with life threatening or uncontrolled bleeding from the gastrointestinal tract in line with NICE TA697

A RED traffic light status is agreed and the decision to treat should be made by a haematology consultant.

Associated BNF Codes

02. Cardiovascular System
02.08.02. Oral anticoagulants
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More